State Street Corp Nymox Pharmaceutical Corp Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.3 - $2.23 $39,642 - $68,001	-30,494 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.48 $912,352 - $1.55 Million	-624,899 Reduced 95.35%	30,494 $48,000
Q1 2021 May 17, 2021	BUY	$2.22 - $3.39 $111,839 - $170,781	50,378 Added 8.33%	655,393 $1.46 Million
Q4 2020 Feb 16, 2021	BUY	$1.84 - $2.83 $200,364 - $308,170	108,894 Added 21.95%	605,015 $1.5 Million
Q3 2020 Nov 10, 2020	BUY	$2.3 - $3.66 $170,517 - $271,345	74,138 Added 17.57%	496,121 $1.22 Million
Q2 2020 Aug 14, 2020	BUY	$2.1 - $4.6 $886,164 - $1.94 Million	421,983 New	421,983 $1.5 Million

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.